Original article
In vitro lymphocyte proliferation by carbamazepine, carbamazepine-10, 11-epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity

https://doi.org/10.1016/0091-6749(88)90059-0Get rights and content

Abstract

In vitro lymphocyte proliferation induced by carbamazepine (CBZ) was evaluated in nine patients with hypersensitivity to this drug. Lymphocytes from all hypersensitive patients responded by significantly enhanced DNA synthesis to CBZ when patients were compared with 33 tested control subjects. However, lymphocytes from five of six hypersensitive patients were not stimulated by carbamazepine-10, 11-epoxide, and oxcarbazepine (OXC), and this was confirmed clinically in two CBZ hypersensitive patients with OXC therapy. The results indicate that OXC may be suitable as an alternative therapy in some patients with CBZ hypersensitivity.

References (10)

There are more references available in the full text version of this article.

Cited by (67)

  • Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia

    2020, The Lancet Neurology
    Citation Excerpt :

    Hence, if one drug is not sufficiently effective the other one should be tried. However, if the first drug causes an allergic reaction, caution should be taken because of possible cross-reactivity.62 The drugs should be titrated slowly to the highest dose needed to control the pain with continuous monitoring of side-effects.63

  • Anticonvulsant agents

    2013, Drug-Induced Liver Disease
  • Activation of T cells by carbamazepine and carbamazepine metabolites

    2006, Journal of Allergy and Clinical Immunology
    Citation Excerpt :

    This is often problematic because patients hypersensitive to 1 anticonvulsant may develop a hypersensitivity reaction to the alternative medication.29 Zakrzewska and Ivanyi17 have reported that lymphocytes from carbamazepine-hypersensitive patients are not stimulated by oxcarbazepine, and therefore suggested that oxcarbazepine may be suitable as a safe alternative drug treatment. However, clinical data show that approximately 25% of carbamazepine-hypersensitive patients cross-react with oxcarbazepine in vivo.30

View all citing articles on Scopus
1

Dr. J. M. Zakrzewska received a grant from the Welton Foundation and from the Endowment Committee of the British Association of Oral and Maxillofacial Surgeons.

View full text